Stereotactic Body Radiotherapy Plus Rucosopasem in Locally Advanced or Borderline Resectable Pancreatic Cancer: GRECO-2 Phase II Study Design

References

• American Cancer Society . Cancer Facts & Figures 2023 (2023). Available at: www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2023/2023-cancer-facts-and-figures.pdf (Accessed: 19 July 2023 ).
   Google Scholar
• Murphy JE, Wo JY, Ryan DPet al. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase II Clinical Trial. JAMA Oncol. 4(7), 963–969 (2018).
   PubMed Web of Science ®Google Scholar
• Palta M, Godfrey D, Goodman KAet al. Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Pract. Radiat. Oncol. 9(5), 322–332 (2019).
   PubMed Web of Science ®Google Scholar
• Lambert A, Schwarz L, Borbath Iet al. An update on treatment options for pancreatic adenocarcinoma. Ther. Adv. Med. Oncol. 11, 1758835919875568 (2019).
   Web of Science ®Google Scholar
• Maggino L, Malleo G, Marchegiani Get al. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. JAMA Surg. 154(10), 932–942 (2019).
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network . Pancreatic Adenocarcinoma. Version 1.2022. (Accessed 3 October 2022 ).
   Google Scholar
• Hammel P, Huguet F, van Laethem JLet al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA 315(17), 1844–1853 (2016).
   PubMed Web of Science ®Google Scholar
• Jang JY, Han Y, Lee Het al. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase II/3 Trial. Ann. Surg. 268(2), 215–222 (2018).
   PubMed Web of Science ®Google Scholar
• Versteijne E, Suker M, Groothuis Ket al. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. J. Clin. Oncol. 38(16), 1763–1773 (2020).
   PubMed Web of Science ®Google Scholar
• Versteijne E, van Dam JL, Suker Met al. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. J. Clin. Oncol. 40(11), 1220–1230 (2022).
   PubMed Web of Science ®Google Scholar
• Krishnan S, Chadha AS, Suh Yet al. Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation. Int. J. Radiat. Oncol. Biol. Phys. 94(4), 755–765 (2016).
   PubMed Web of Science ®Google Scholar
• Rudra S, Jiang N, Rosenberg SAet al. Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. Cancer Med. 8(5), 2123–2132 (2019).
   PubMed Web of Science ®Google Scholar
• Iyengar P, Kavanagh BD, Wardak Zet al. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J. Clin. Oncol. 32(34), 3824–3830 (2014).
   PubMed Web of Science ®Google Scholar
• Timmerman R, Paulus R, Galvin Jet al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303(11), 1070–1076 (2010).
   PubMed Web of Science ®Google Scholar
• Zhong J, Patel K, Switchenko Jet al. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation. Cancer 123(18), 3486–3493 (2017).
   PubMed Web of Science ®Google Scholar
• Murphy JD, Christman-Skieller C, Kim J, Dieterich S, Chang DT, Koong AC. A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 78(5), 1420–1426 (2010).
   PubMed Web of Science ®Google Scholar
• Chuong MD, Bryant J, Mittauer KEet al. Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided Radiation Therapy With On-Table Adaptive Replanning and Elective Nodal Irradiation for Inoperable Pancreas Cancer. Pract. Radiat. Oncol. 11(2), 134–147 (2021).
   PubMed Web of Science ®Google Scholar
• Taniguchi C, Frakes J, Aguilera Tet al. Stereotactic Body Radiation Therapy with or without a selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled phase 1b/2 trial. Lancet Oncol. 24(12), 1387–1398 (2023).
   PubMed Web of Science ®Google Scholar
• Hassanzadeh C, Rudra S, Bommireddy Aet al. Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation. Adv. Radiat. Oncol. 6(1), 100506 (2021).
   PubMedGoogle Scholar
• Koay EJ, Hanania AN, Hall WAet al. Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach. Pract. Radiat. Oncol. 10(6), e495–e507 (2020).
   PubMed Web of Science ®Google Scholar
• Reyngold M, O’Reilly EM, Varghese AMet al. Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer. JAMA Oncol. 7(5), 735–738 (2021).
   PubMed Web of Science ®Google Scholar
• Parikh PJ, Lee P, Low DAet al. A Multi-Institutional Phase II Trial of Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided On-Table Adaptive Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer. Int. J. Radiat. Oncol. Biol. Phys. 19, S0360-3016(23)00499-6 (2023) ( Online ahead of print).
   Google Scholar
• Bryant JM, Palm RF, Liveringhouse Cet al. Surgical and Pathologic Outcomes of Pancreatic Adenocarcinoma (PA) After Preoperative Ablative Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy (A-SMART). Adv. Radiat. Oncol. 7(6), 101045 (2022).
   PubMedGoogle Scholar
• Katz MHG, Shi Q, Meyers Jet al. Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase II Randomized Clinical Trial. JAMA Oncol. 8(9), 1263–1270 (2022).
   PubMed Web of Science ®Google Scholar
• Hall WA, Dawson LA, Hong TSet al. Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. J. Clin. Oncol. 39(34), 3773–3777 (2021).
   PubMed Web of Science ®Google Scholar
• Riley DP, Schall OF. Structure-Activity Studies and the Design of Synthetic Superoxide Dismutase (SOD) Mimetics as Therapeutics. Template Effects and Molecular Organization. Advances in Inorganic Chemistry (2006).233–263
   Google Scholar
• Doskey CM, Buranasudja V, Wagner BAet al. Tumor cells have decreased ability to metabolize H2O2: implications for pharmacological ascorbate in cancer therapy. Redox. Biol. 10, 274–284 (2016).
   PubMed Web of Science ®Google Scholar
• El-Mahdy MA, Alzarie YA, Hemann C, Badary OA, Nofal S, Zweier JL. The novel SOD mimetic GC4419 increases cancer cell killing with sensitization to ionizing radiation while protecting normal cells. Free Radic. Biol. Med. 160, 630–642 (2020).
   PubMed Web of Science ®Google Scholar
• Sishc BJ, Ding L, Nam TKet al. Avasopasem manganese synergizes with hypofractionated radiation to ablate tumors through the generation of hydrogen peroxide. Sci. Transl. Med. 13(593), eabb3768 (2021).
   PubMed Web of Science ®Google Scholar
• Mellon EA, Hoffe SE, Springett GMet al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta. Oncol. 54(7), 979–985 (2015).
   PubMed Web of Science ®Google Scholar